Add-on Chinese medicine for hospitalized chronic obstructive pulmonary disease (CHOP): A cohort study of hospital registry

医学 慢性阻塞性肺病 倾向得分匹配 内科学 恶化 危险系数 队列 回顾性队列研究 药方 比例危险模型 临床终点 队列研究 置信区间 随机对照试验 药理学
作者
Ning Xu,Kunyu Zhong,Haibin Yu,Zixin Shu,Kai Chang,Qiguang Zheng,Haoyu Tian,Ling Zhou,Wei Wang,Yunyan Qu,Baoyan Liu,Xuezhong Zhou,Kam Wa Chan,Jiansheng Li
出处
期刊:Phytomedicine [Elsevier]
卷期号:109: 154586-154586 被引量:3
标识
DOI:10.1016/j.phymed.2022.154586
摘要

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally. The effect of Chinese medicine (CM) on mortality during acute exacerbation of COPD is unclear. We evaluated the real-world effectiveness of add-on personalized CM in hospitalized COPD patients with acute exacerbation.This is a retrospective cohort study with new-user design. All electronic medical records of hospitalized adult COPD patients (n = 4781) between July 2011 and November 2019 were extracted. Personalized CM exposure was defined as receiving CM that were prescribed, and not in a fixed form and dose at baseline. A 1:1 matching control cohort was generated from the same source and matched by propensity score. Primary endpoint was mortality. Multivariable Cox regression models were used to estimate the hazard ratio (HR) adjusting the same set of covariates (most prevalent with significant inter-group difference) used in propensity score calculation. Secondary endpoints included the change in hematology and biochemistry, and the association between the use of difference CMs and treatment effect. The prescription pattern was also assessed and the putative targets of the CMs on COPD was analyzed with network pharmacology approach.4325 (90.5%) patients were included in the analysis. The mean total hospital stay was 16.7 ± 11.8 days. In the matched cohort, the absolute risk reduction by add-on personalized CM was 5.2% (3.9% vs 9.1%). The adjusted HR of mortality was 0.13 (95% CI: 0.03 to 0.60, p = 0.008). The result remained robust in the sensitivity analyses. The change in hematology and biochemistry were comparable between groups. Among the top 10 most used CMs, Poria (Fu-ling), Citri Reticulatae Pericarpium (Chen-pi) and Glycyrrhizae Radix Et Rhizoma (Gan-cao) were associated with significant hazard reduction in mortality. The putative targets of the CM used in this cohort on COPD were related to Jak-STAT, Toll-like receptor, and TNF signaling pathway which shares similar mechanism with a range of immunological disorders and infectious diseases.Our results suggest that add-on personalized Chinese medicine was associated with significant mortality reduction in hospitalized COPD patients with acute exacerbation in real-world setting with minimal adverse effect on liver and renal function. Further randomized trials are warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
juanjuan应助SC采纳,获得10
刚刚
1秒前
ZQ2415719完成签到,获得积分10
1秒前
2秒前
panhanfu发布了新的文献求助10
3秒前
大爱仙尊完成签到,获得积分10
4秒前
贰陆完成签到,获得积分10
5秒前
5秒前
怕黑海冬发布了新的文献求助10
6秒前
mo完成签到,获得积分10
7秒前
8秒前
9秒前
9秒前
思源应助慕容采文采纳,获得10
10秒前
听闻韬声依旧完成签到 ,获得积分10
12秒前
天天快乐应助瘦瘦怜阳采纳,获得10
12秒前
zyh应助无语采纳,获得10
12秒前
13秒前
14秒前
e746700020完成签到,获得积分10
14秒前
15秒前
SiDi发布了新的文献求助30
16秒前
矮小的珠发布了新的文献求助10
16秒前
17秒前
panhanfu完成签到,获得积分10
18秒前
18秒前
情怀应助SiDi采纳,获得10
19秒前
所所应助看文献采纳,获得10
21秒前
俗签发布了新的文献求助10
21秒前
小卡啦发布了新的文献求助10
23秒前
Lensin发布了新的文献求助10
23秒前
独特觅翠发布了新的文献求助10
23秒前
zxx完成签到,获得积分10
24秒前
28秒前
30秒前
31秒前
SciGPT应助cc采纳,获得10
32秒前
科研同路人完成签到,获得积分0
32秒前
33秒前
无名花生完成签到 ,获得积分10
35秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
XAFS for Everyone 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3145183
求助须知:如何正确求助?哪些是违规求助? 2796550
关于积分的说明 7820359
捐赠科研通 2452897
什么是DOI,文献DOI怎么找? 1305280
科研通“疑难数据库(出版商)”最低求助积分说明 627448
版权声明 601449